Pharmaceuticals, Biotechnology and Life Sciences
– Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients…
– New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment –…
– Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented…
Following a positive study where satralizumab was added to baseline therapy, satralizumab monotherapy significantly reduced risk of relapse by 55%…
– Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in…
– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer…
The MINISTONE-2 study showed XOFLUZA, given as a new oral suspension, is a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years –
Approval based on data showing Kadcyla cut the risk of diseaserecurring by half compared to Herceptin in the adjuvant setting forspecific patients with HER2-positive early breast cancer
New data will be presented for risdiplam, an investigational oralsurvival motor neuron 2 (SMN2) splicing modifier for SMA, which isdesigned to increase and sustain SMN protein levels in the centralnervous system (CNS) and throughout the body.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),today announced that the U.S. Food and Drug Administration (FDA)approved Tecentriq® (atezolizumab), in combinationwith carboplatin and etoposide (chemotherapy), for the initial(first-line) treatment of adults with extensive-stage small cell lungcancer (ES-SCLC).